Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Adagio Medical Holdings, Inc Common Stock (ADGM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ADGM (1-star) is a SELL. SELL since 1 days. Profits (-13.70%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -40.81% | Avg. Invested days 35 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.77M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.04 | 52 Weeks Range 0.62 - 9.34 | Updated Date 06/16/2025 |
52 Weeks Range 0.62 - 9.34 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5822.92% |
Management Effectiveness
Return on Assets (TTM) -82.76% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22385905 | Price to Sales(TTM) 29.11 |
Enterprise Value 22385905 | Price to Sales(TTM) 29.11 | ||
Enterprise Value to Revenue 370.25 | Enterprise Value to EBITDA - | Shares Outstanding 15381600 | Shares Floating 3170756 |
Shares Outstanding 15381600 | Shares Floating 3170756 | ||
Percent Insiders 0.29 | Percent Institutions 85.46 |
Upturn AI SWOT
Adagio Medical Holdings, Inc Common Stock
Company Overview
History and Background
Adagio Medical is a medical technology company focused on developing and commercializing innovative cardiac ablation technologies for the treatment of atrial fibrillation (Afib). Founded to address the limitations of existing Afib treatments, the company aims to improve patient outcomes through advanced cryoablation techniques. Details on their founding year, significant milestones, and evolution are currently limited publicly.
Core Business Areas
- Cryoablation Technologies: Development and commercialization of cryoablation catheters and systems for treating Afib.
Leadership and Structure
Information regarding the specific leadership team and organizational structure is not readily available in public sources. Public filings, when available, would provide further details.
Top Products and Market Share
Key Offerings
- iCLAS Catheter and Cryo Console: A cryoablation system used to create durable lesions in the heart to treat atrial fibrillation. Market share data is not publicly available. Competitors include Medtronic (MDT), Abbott (ABT), Boston Scientific (BSX), and Biosense Webster (JNJ).
Market Dynamics
Industry Overview
The cardiac ablation market is driven by the increasing prevalence of atrial fibrillation and the demand for less invasive treatment options. Growth is fueled by technological advancements and aging populations.
Positioning
Adagio Medical is positioned as an innovator in cryoablation technology. Their competitive advantage lies in their proprietary iCLAS technology. More data is needed to further expand on this information.
Total Addressable Market (TAM)
The total addressable market for atrial fibrillation treatment is estimated to be in the billions of dollars. Adagio Medical is positioned to capture a share of this market with its cryoablation technology, but specific TAM data for Adagio is not publicly available.
Upturn SWOT Analysis
Strengths
- Innovative cryoablation technology
- Potential for improved patient outcomes
- Focus on a large and growing market
Weaknesses
- Limited publicly available financial data
- Dependence on regulatory approvals
- Competition from established players
Opportunities
- Expansion into new markets
- Development of new applications for cryoablation technology
- Partnerships with other medical device companies
Threats
- Technological obsolescence
- Changes in reimbursement policies
- Increased competition
Competitors and Market Share
Key Competitors
- MDT
- ABT
- BSX
- JNJ
Competitive Landscape
Adagio Medical faces strong competition from established medical device companies with larger resources and broader product portfolios. Adagiou2019s innovation in cryoablation provides them a potential edge but market penetration remains a challenge.
Growth Trajectory and Initiatives
Historical Growth: Data not available for Adagio Medical
Future Projections: Data not available for Adagio Medical
Recent Initiatives: Information on recent initiatives is not readily available in public sources.
Summary
Adagio Medical is a medical technology company with an innovative cryoablation system for treating atrial fibrillation. They operate in a large and growing market but face strong competition from established players. While detailed financials are unavailable, the company's success depends on regulatory approvals and its ability to capture market share. Continued innovation and strategic partnerships will be critical for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Analyst estimates (where available)
Disclaimers:
The information provided is based on publicly available data and is for informational purposes only. It should not be considered financial advice. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adagio Medical Holdings, Inc Common Stock
Exchange NASDAQ | Headquaters Laguna Hills, CA, United States | ||
IPO Launch date 2024-08-01 | CEO & Director Mr. Todd Usen | ||
Sector Healthcare | Industry Medical Devices | Full time employees 80 | Website https://adagiomedical.com |
Full time employees 80 | Website https://adagiomedical.com | ||
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.